Of significance, the tumorigenic CD44+ cell populations in both Du145 and LAPC9 commonly upregulate 14 genes involved in development (FGF1, FGFR1, and DVL1), cell cycle (RB1, CDC2, CCND2, and CCNA2), and neuronal activity (TUBB3 and NEUROG2), providing potential therapeutic targets for the CD44+ PCa cells. This evidence concerns the gene DVL1 and posterior cortical atrophy.